OncoMatch/Non-Hodgkin Lymphoma (NHL)/PD-L1 (CD274)

Non-Hodgkin Lymphoma (NHL)PD-L1 (CD274) Clinical Trials

PD-L1 expression is an eligibility or stratification biomarker across multiple NHL subtypes: primary mediastinal B-cell lymphoma (PMBCL) shows high PD-L1/PD-L2 expression due to 9p24.1 amplification and responds well to pembrolizumab. Cutaneous T-cell lymphoma, peripheral T-cell lymphoma, and other NHL subtypes have ongoing PD-1 inhibitor trials. Trials explore checkpoint immunotherapy in PD-L1-enriched NHL subtypes, combinations with BTK or BCL2 inhibitors, and bispecific antibody plus IO regimens.